Tracking Remyelination: Do You See What I See?
Several new imaging modalities are aimed at evaluating possible remyelination in patients with multiple sclerosis. This article discusses how the techniques work and their potential applications to MS, as well as their limitations.
For nearly 15 years, magnetic resonance imaging has been an important tool for...
Clinical Research
Incomplete B-Cell Depletion Linked to Fewer MRI Lesions
In a dose-ranging study of the anti-CD20 antibody ofatumumab, even incomplete depletion of peripheral B cells was associated with a reduced number of MRI brain lesions in patients with RRMS
When treating relapsing-remitting multiple sclerosis patients with anti-B cell antibodies, complete depletion of B cells is...
Clinical Research, Drug Development, Meetings
Can Gut Microbes Provide Answers About MS?
Is the gut as interesting as the brain? Researchers probing the ecosystem of the human gut microbiome have identified organisms that are enriched or depleted in MS patients, possibly yielding clues about pathogenic mechanisms. Meanwhile, introducing a nonhuman pathogen into the gut is being investigated as a possible treatment approach.
“I am going to argue that the gut is as interesting as the brain,” said...
Clinical Research
MS Research Roundup: May 27, 2014
Sex, Drugs, and Preclinical Research; Promising Biomarker for Progressive MS; Journalist With MS Finds Hope in Stem Cell Trial
Items of interest to multiple sclerosis researchers from around the Web...
Clinical Research, Drug Development, Laboratory Research, People
MS Patient, Ph.D.: Pros and Cons of the First Generic DMT
The Copaxone patent expired on May 24, which could lead to cost-based DMT choice
This Memorial Day weekend marked not only the unofficial start of summer but also...
Drug Development, People
Papers: 16 May 2014 - 23 May 2014
Simvastatin
Editors' Pick
Editors' Pick
Pages
